Clinical Trials Logo

Clinical Trial Summary

This pilot study may yield important research findings on how to adapt exercise treatment for depression among adolescents. Potential public health benefits from this study include a reduction of adolescent depression and problems associated with untreated depression in young adults including suicide, substance abuse, cigarette smoking, teen pregnancy, impaired psychosocial functioning and school failure. In addition, because this study prescribes physical activity as a treatment for depression, additional public health benefits may include a reduction in chronic diseases such as obesity, diabetes and heart disease, all of which are associated with sedentary behavior.


Clinical Trial Description

Adolescent depression is a major public health problem in the United States and throughout the world. Major depressive disorder (MDD) in adolescence is common with point prevalence rates of 3% to 9%. In the U.S., it is estimated that by the time adolescents reach the age of 17, 14% will have experienced at least one episode of major depressive disorder. Effective treatments of adolescent depression are clearly needed despite the fact that in the past 10-15 years, there has been a dramatic increase in studies of the efficacy of medications, primarily the selective serotonin reuptake inhibitors (SSRIs) and of cognitive behavioral therapy (CBT). Medications and CBT rarely result in complete and lasting remission of symptoms, and residual symptoms are associated with a high rate of relapse. In most studies, a positive response is defined as a 30-50% improvement in symptoms and/or a global rating that the subject is much or very much improved. In adults, exercise has been used as a mono-therapy and as an augmentation therapy with antidepressant medication. Our recently completed randomized trial of exercise treatment in adults found response and remission rates of 46% and 42%, in those randomized to a public health dose of exercise. In adolescents, data on the use of exercise to treat MDD is relatively sparse. A 2006 Cochrane review of exercise to prevent and treat depression in adolescents found a small effect size in support of exercise, but the conclusion is based on evidence from a small number of randomized clinical trials of low methodological quality. In this exploratory R34, the specific aims of this application are to: 1) Develop a detailed Manual of Procedures (MOP) to conduct an acute-phase randomized trial of exercise to treat adolescent depression; 2) Develop estimates of recruitment yield from tests of various recruitment strategies; and, 3) Pilot test trial methodologies in (n=40) adolescents diagnosed with depression to ascertain estimates of treatment effect sizes, adherence and drop-out rates. To achieve these aims, the project is organized into 3 phases. Phase I will be the development of the first draft MOP that will adapt procedures developed from a previous trial examining two doses of exercise in treatment of adult MDD. Phase II will test specific recruitment methodologies to determine recruitment yields for each strategy and will pilot test screening procedures developed in Phase I. Phase III will be a pilot test of the intervention and will include development of baseline and outcome measures of exercise and depression; development and implementation of the experimental exercise treatment; and determination of the effects of exercise on depressive symptoms. Following the pilot study, we will finalize all procedures for the MOP and obtain estimates of effect sizes, adherence and drop out rates. These data will allow us to specify all study procedures necessary to meet standards of high methodological quality for a future, larger-scale, controlled study of exercise in depressed youth and will provide us with needed experience. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00964054
Study type Interventional
Source National Institute of Mental Health (NIMH)
Contact
Status Completed
Phase Phase 1
Start date September 2012
Completion date February 2013

See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Recruiting NCT05570110 - Enoxolone in Major Depression - Biomarker-outcome Relationship Phase 1/Phase 2
Completed NCT02530164 - Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression N/A
Completed NCT01447602 - A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Phase 3
Completed NCT00517387 - The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression Phase 3
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Terminated NCT04712968 - Efficacy of Daylight as Adjunctive Treatment in Patients With Depression N/A
Enrolling by invitation NCT04717921 - Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
Recruiting NCT03358056 - Effects of Mindfulness Based Cognitive Therapy on Emotional Processing N/A
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02111915 - Thinking Healthy Program - Peer Delivered (Pakistan) N/A
Completed NCT02104232 - Thinking Healthy Program - Peer Delivered, India (THPP-I) N/A
Terminated NCT01219686 - EScitalopram PIndolol ONset of Action Phase 2/Phase 3
Completed NCT00158990 - Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. Phase 3
Completed NCT01049347 - Amitriptyline and Paroxetine Treatment of Major Depression Phase 3
Completed NCT03268434 - Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care N/A
Completed NCT01880957 - PET and MRI Brain Imaging of Bipolar Disorder N/A
Completed NCT04420793 - Voice Changes During ECT
Not yet recruiting NCT01694030 - Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study Phase 1
Completed NCT00265291 - Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group Phase 2